1. Home
  2. AMCX vs AUTL Comparison

AMCX vs AUTL Comparison

Compare AMCX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

HOLD

Current Price

$9.36

Market Cap

411.2M

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.51

Market Cap

388.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
AUTL
Founded
1980
2014
Country
United States
United Kingdom
Employees
1738
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
411.2M
388.6M
IPO Year
2011
2025

Fundamental Metrics

Financial Performance
Metric
AMCX
AUTL
Price
$9.36
$1.51
Analyst Decision
Sell
Strong Buy
Analyst Count
4
4
Target Price
$7.33
$8.50
AVG Volume (30 Days)
465.5K
1.2M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
132.55
N/A
EPS
N/A
N/A
Revenue
$2,311,801,000.00
$10,120,000.00
Revenue This Year
N/A
$80.32
Revenue Next Year
N/A
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$5.41
$1.18
52 Week High
$10.65
$2.70

Technical Indicators

Market Signals
Indicator
AMCX
AUTL
Relative Strength Index (RSI) 49.23 45.03
Support Level $6.90 $1.41
Resistance Level $10.32 $1.52
Average True Range (ATR) 0.52 0.12
MACD -0.12 -0.02
Stochastic Oscillator 18.87 25.60

Price Performance

Historical Comparison
AMCX
AUTL

About AMCX AMC Networks Inc.

AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: